CLINICAL TRIALS PROFILE FOR AVASTIN

Biosimilar Clinical Trials for AVASTIN

This table shows clinical trials for biosimilars. See the next table for all clinical trials

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02069704 ↗	Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) in First-line Treatment mCRC Patients	Completed	Laboratorio Elea Phoenix S.A.	Phase 1	2014-10-29	This is a multicenter, open label, randomized bioequivalence study of BEVZ92 (bevacizumab biosimilar) and Avastin® with 2 parallel arms to compare the pharmacokinetic (PK) profile of BEVZ92 and Avastin® in combination with FOLFOX (any) or FOLFIRI chemotherapy. FOLFOX (any) or FOLFIRI will be chosen as per investigator criteria based on the hospital standard of care.
NCT02069704 ↗	Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) in First-line Treatment mCRC Patients	Completed	Laboratorio Elea S.A.C.I.F. y A.	Phase 1	2014-10-29	This is a multicenter, open label, randomized bioequivalence study of BEVZ92 (bevacizumab biosimilar) and Avastin® with 2 parallel arms to compare the pharmacokinetic (PK) profile of BEVZ92 and Avastin® in combination with FOLFOX (any) or FOLFIRI chemotherapy. FOLFOX (any) or FOLFIRI will be chosen as per investigator criteria based on the hospital standard of care.
NCT02069704 ↗	Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) in First-line Treatment mCRC Patients	Completed	Libbs Farmacêutica LTDA	Phase 1	2014-10-29	This is a multicenter, open label, randomized bioequivalence study of BEVZ92 (bevacizumab biosimilar) and Avastin® with 2 parallel arms to compare the pharmacokinetic (PK) profile of BEVZ92 and Avastin® in combination with FOLFOX (any) or FOLFIRI chemotherapy. FOLFOX (any) or FOLFIRI will be chosen as per investigator criteria based on the hospital standard of care.

All Clinical Trials for AVASTIN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00016107 ↗	Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer	Completed	National Cancer Institute (NCI)	Phase 2	2001-06-01	Phase II trial to study the effectiveness of combination chemotherapy plus monoclonal antibody therapy in treating patients who have metastatic prostate cancer that has not responded to previous hormone therapy. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as bevacizumab may stop the growth of cancer cells by stopping blood flow to the tumor. Combining monoclonal antibody therapy with chemotherapy may kill more tumor cells.
NCT00017394 ↗	Bevacizumab Plus Vinorelbine in Treating Patients With Stage IV Breast Cancer	Completed	National Cancer Institute (NCI)	Phase 2	2001-03-01	Phase II trial to study the effectiveness of bevacizumab combined with vinorelbine in treating patients who have stage IV breast cancer. Monoclonal antibodies such as bevacizumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining monoclonal antibody with chemotherapy may kill more cancer cells
NCT00021060 ↗	Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer	Completed	National Cancer Institute (NCI)	Phase 2/Phase 3	2002-08-01	Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them. Combining chemotherapy with a monoclonal antibody may kill more tumor cells. This randomized phase II/III trial is to see if combination chemotherapy works better with or without bevacizumab in treating patients who have advanced, metastatic, or recurrent non-small cell lung cance

Clinical Trial Conditions for AVASTIN

Condition Name

Condition Name for AVASTIN
Intervention	Trials
Colorectal Cancer	94
Breast Cancer	82
Glioblastoma	46

Condition MeSH

Condition MeSH for AVASTIN
Intervention	Trials
Colorectal Neoplasms	188
Carcinoma	148
Carcinoma, Non-Small-Cell Lung	128

Clinical Trial Locations for AVASTIN

Trials by Country

Trials by Country for AVASTIN
Location	Trials
Spain	283
Italy	276
Canada	256
Australia	122
Brazil	108

Trials by US State

Trials by US State for AVASTIN
Location	Trials
Texas	222
California	216
Ohio	179
Florida	175
New York	169

Clinical Trial Progress for AVASTIN

Clinical Trial Phase

Clinical Trial Phase for AVASTIN
Clinical Trial Phase	Trials
PHASE3	1
PHASE2	1
PHASE1	3

Clinical Trial Status

Clinical Trial Status for AVASTIN
Clinical Trial Phase	Trials
Completed	663
Terminated	144
Recruiting	110

Clinical Trial Sponsors for AVASTIN

Sponsor Name

Sponsor Name for AVASTIN
Sponsor	Trials
Genentech, Inc.	218
National Cancer Institute (NCI)	189
Hoffmann-La Roche	149

Sponsor Type

Sponsor Type for AVASTIN
Sponsor	Trials
Other	1189
Industry	769
NIH	200

AVASTIN (bevacizumab): Clinical Trials Update, Market Analysis, and Forward Projection

Last updated: April 27, 2026

What is AVASTIN and how is it positioned commercially?

AVASTIN is the brand name for bevacizumab, a monoclonal antibody that targets VEGF-A. It is marketed globally for multiple oncology indications in combination regimens. In practice, AVASTIN is a mature, label-expansion driven franchise with ongoing lifecycle management via new studies, line-of-therapy extensions, and optimized combinations.

Core commercial attributes

• Established multimodal oncology positioning across tumor types where VEGF-driven angiogenesis is clinically relevant.
• Combination-centric use: real-world prescribing is tied to regimen standards (chemotherapy, immunotherapy, targeted agents) and guideline adoption.
• Biosimilar pressure: revenue has been shaped by introduction and uptake of bevacizumab biosimilars in key markets (EU, US, and select APAC markets).

What do the clinical-trial trends show for bevacizumab/AVASTIN?

Bevacizumab’s clinical program is characterized by:

• Combination trials (with immunotherapy, chemo, and targeted agents).
• Biomarker stratification studies (predictive markers for VEGF axis sensitivity).
• Earlier-line expansion and maintenance/adjunct regimens.
• Geographic and regulatory bridging studies tied to existing label structures.

High-level clinical development pattern

1. Confirmatory and line-extension studies support label optimization rather than replacing the franchise.
2. Regimen-specific trials address competitive differentiation versus other VEGF inhibitors (e.g., small-molecule TKIs) and next-gen antibodies.
3. Oncology-specific operational focus: trials cluster around histology and standard regimen frameworks that already incorporate anti-angiogenic therapy.

What is the current clinical-trial update status?

A full “live” tracker requires a trial-by-trial refresh across clinical registries (ClinicalTrials.gov, EU CTR, WHO ICTRP) with start/primary completion status, endpoints, and publications. In the absence of a provided registry export or a fixed trial list, a complete and accurate update cannot be produced.

How big is AVASTIN’s market and what is the competitive structure?

Market demand drivers

• Anti-VEGF remains embedded in standard-of-care regimens for several major solid tumors, particularly where angiogenesis blockade improves survival outcomes in combination settings.
• Oncology incidence and treatment intensity sustain baseline demand even as cure rates evolve.

Competitive landscape

Direct competition

• Bevacizumab biosimilars: direct class substitution across most approved indications.
• Alternative anti-angiogenic agents: VEGFR TKIs and next-gen antibodies compete in specific tumor settings and lines of therapy depending on guideline and payer preferences.

Substitution dynamics

• Biosimilars compress pricing, shift contracts, and reduce share for branded originator use unless protected by differentiated uptake (tender dynamics, procurement policies, and physician preference in constrained settings).

What do the historical revenue and label dynamics imply for projection?

Projection framework used

For a mature biologic like AVASTIN, projection typically decomposes into:

• Volume effect (patient numbers, regimen prevalence, line-of-therapy migration)
• Price effect (biosimilar-driven erosion, tender and payer contracting)
• Mix effect (shift across tumor types and lines; uptake of specific combination regimens)
• Share effect (originator vs biosimilar channel allocation)

Base-case outlook (directional)

• Revenue growth is unlikely without new major label expansions that are strong enough to offset price erosion.
• Market share for originator AVASTIN likely continues to decline in markets where bevacizumab biosimilars have established tender penetration.
• Net market value may stabilize in volume terms while shrinking in monetary terms if pricing continues to compress.

What are the most investable growth or risk levers for AVASTIN?

Key upside levers

• Sustained uptake in high-burden tumor types where anti-VEGF remains guideline-congruent.
• New regimen approvals that expand use earlier in lines of therapy or expand combinations with newer oncology backbones (where clinically proven).
• Lifecycle differentiation via specific combination evidence and real-world guideline uptake.

Key downside levers

• Further biosimilar penetration (tender wins, automated substitution policies, and reference pricing effects).
• Switching to alternative anti-angiogenic mechanisms when they demonstrate superior efficacy, tolerability, or convenience in given populations.
• Safety-management constraints affecting prescribing patterns (e.g., hypertension, thromboembolic events, bleeding risks) which can shift clinician preference in subgroups.

What is the forward projection for AVASTIN’s market performance?

A complete forecast requires: current revenue by geography, biosimilar penetration rates by indication, uptake curves, tender pricing, and forecast scenarios from a named market dataset. Without those inputs, a complete and accurate quantitative projection cannot be produced.

What can be stated with certainty about AVASTIN’s market trajectory?

Even without a numerical forecast, the trajectory for a branded originator bevacizumab product is structurally determined by:

• Biosimilar competition that reduces price and share.
• Continued high utilization of VEGF-targeting regimens in multiple oncology standards.
• Lifecycle activity that sustains label relevance but rarely resets revenue without major new indication breakthroughs.

Clinical trial and market events to watch (actionable list)

1. Regulatory decisions tied to combination regimens that may expand label scope (new tumor types, earlier-line use, maintenance strategies).
2. Publication updates of phase 3 and phase 2b trials that change clinical practice in anti-angiogenic positioning.
3. Biosimilar tender cycles and reference pricing changes in major procurement markets.
4. Guideline updates that specify anti-VEGF use within chemo-immunotherapy backbones or maintenance schedules.

Key Takeaways

• AVASTIN (bevacizumab) is a mature, combination-led anti-VEGF oncology franchise with demand anchored to multiple solid tumor standards of care.
• The clinical program is dominated by regimen optimization, line-of-therapy expansion, and biomarker refinement rather than replacement of the therapeutic class.
• Market performance is structurally constrained by biosimilar-driven price erosion and share compression even as clinical utilization remains durable.
• A complete quantitative clinical-trial status update and market projection requires a defined trial list and current revenue/penetration dataset; without them, only the structural trajectory can be stated.

FAQs

1) Does AVASTIN face the same level of biosimilar pressure in all markets?

No. Biosimilar uptake and tender penetration vary materially by geography, payer rules, and procurement contracting.

2) What typically drives AVASTIN label expansion?

Most expansions come through combination evidence, line-of-therapy shifts, and tumor-specific confirmatory trials.

3) Are the newest trials aiming to replace bevacizumab or refine its use?

For a mature asset, most trials refine use within approved therapeutic frameworks and compete through regimen optimization rather than class replacement.

4) What is the main risk to branded AVASTIN revenue?

Pricing and share erosion from bevacizumab biosimilars, amplified by payer procurement structures.

5) What is the main potential upside?

Strong label expansions in earlier lines or high-volume tumor indications that can outpace pricing erosion.

---

References

[1] ClinicalTrials.gov. Bevacizumab (search results and study records). https://clinicaltrials.gov/
[2] European Medicines Agency (EMA). Avastin (bevacizumab) EPAR and product information. https://www.ema.europa.eu/
[3] U.S. Food and Drug Administration (FDA). Avastin (bevacizumab) prescribing information and approvals. https://www.fda.gov/